Evolent Health (NYSE:EVH) Price Target Cut to $12.00 by Analysts at Stephens

Evolent Health (NYSE:EVH) had its target price lowered by Stephens from $16.00 to $12.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the technology company’s stock. Stephens’ price objective indicates a potential upside of 17.53% from the stock’s previous close.

A number of other analysts also recently commented on EVH. Citigroup dropped their price objective on Evolent Health from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Barclays cut their price target on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, November 11th. UBS Group lowered their price objective on shares of Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, January 16th. Oppenheimer cut their target price on shares of Evolent Health from $34.00 to $28.00 and set an “outperform” rating for the company in a research note on Monday, November 18th. Finally, Royal Bank of Canada decreased their price target on shares of Evolent Health from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $21.62.

Evolent Health Price Performance

NYSE EVH opened at $10.21 on Tuesday. Evolent Health has a 12 month low of $9.88 and a 12 month high of $35.00. The firm has a market capitalization of $1.19 billion, a PE ratio of -11.22 and a beta of 1.45. The company’s 50 day simple moving average is $11.69 and its 200 day simple moving average is $20.66. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04.

Institutional Investors Weigh In On Evolent Health

Hedge funds have recently bought and sold shares of the business. Covestor Ltd grew its stake in Evolent Health by 138.1% during the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Evolent Health by 5,365.5% during the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after purchasing an additional 1,556 shares during the period. Quarry LP purchased a new position in Evolent Health during the second quarter valued at approximately $32,000. Creative Planning increased its stake in Evolent Health by 12.2% in the 2nd quarter. Creative Planning now owns 18,091 shares of the technology company’s stock valued at $346,000 after buying an additional 1,973 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in Evolent Health in the 2nd quarter worth approximately $61,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.